Ophir Shahaf
Angel Investor @ HBL Hadasit Bio Holdings
Ophir Shahaf is a seed investor at HBL Hadasit Bio Holdings focused on Medical and Health Care. Ophir Shahaf
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ophir Shahaf invests in
Stages Ophir Shahaf invests in
Countries Ophir Shahaf invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (29%)
- Health Care 1 (14%)
- Biotechnology 1 (14%)
- Pharmaceutical 1 (14%)
- Clinical Trials 1 (14%)
Stage
- Seed 2 (29%)
- Funding Round 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| YonaLink is a global network of over 30,000 medical centers that provides EHR-to-EDC streaming and AI-driven CRF data mapping. YonaLink collects clinical trial data in real-time, improves trial efficiency and data quality, reduces medical center staff burnout, and provides wider access to novel patient care opportunities. | $6M / Seed / Nov 08, 2022 | ||
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $2.4M / Sep 09, 2013 | ||
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $3M / Apr 14, 2011 | ||
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $1.5M / Dec 01, 2009 | ||
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $500K / Jan 28, 2009 | ||
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | Seed | ||
| See all 7 investments → | |||
Co-Investors
About HBL Hadasit Bio Holdings
Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.
HBL Hadasit Bio Holdings Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Rafi Hofstein
President & CEO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ophir Shahaf invest in?
Ophir Shahaf invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Funding Round stage. Most of the 7 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ophir Shahaf?
Public channels for Ophir Shahaf include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ophir Shahaf last invest?
The most recent investment recorded for Ophir Shahaf closed in Nov 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
